Squarepoint Ops LLC Sells 65,683 Shares of uniQure N.V. $QURE

Squarepoint Ops LLC lowered its stake in uniQure N.V. (NASDAQ:QURE) by 19.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,300 shares of the biotechnology company’s stock after selling 65,683 shares during the period. Squarepoint Ops LLC’s holdings in uniQure were worth $12,911,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of QURE. Woodline Partners LP lifted its stake in shares of uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares during the last quarter. Legal & General Group Plc bought a new stake in uniQure during the 2nd quarter worth $497,000. Marshall Wace LLP grew its position in uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after acquiring an additional 163,749 shares during the last quarter. California State Teachers Retirement System acquired a new position in uniQure in the 2nd quarter worth about $540,000. Finally, Ameriprise Financial Inc. raised its position in uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after purchasing an additional 212,218 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Barclays reduced their price target on uniQure from $65.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, July 30th. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a report on Wednesday, June 17th. Royal Bank Of Canada lifted their target price on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Wells Fargo & Company upped their price target on shares of uniQure from $60.00 to $75.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Finally, Mizuho upped their price target on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average price target of $65.00.

uniQure Price Performance

Shares of QURE opened at $46.00 on Thursday. The firm has a market cap of $3.19 billion, a PE ratio of -11.47 and a beta of 0.94. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The business’s 50 day moving average price is $44.25 and its two-hundred day moving average price is $30.88. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the previous year, the business posted ($0.69) earnings per share. On average, equities analysts anticipate that uniQure N.V. will post -3.82 EPS for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, Director Jack Kaye sold 21,167 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. The trade was a 44.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider owned 148,235 shares of the company’s stock, valued at $6,881,068.70. This trade represents a 16.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 347,412 shares of company stock valued at $15,712,415. Insiders own 4.65% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.